Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of human cancer
Wednesday, 14. September 2011 | 14:45 Uhr
Speaker
Organisation
Reporting
According to Professor Rudolf Aebersold of ETH Zurich, statistics show that life expectancy of patients increases if cancer is diagnosed at an early stage. With cancer genetics, patients can be alerted that they are at risk and their awareness for the disease can be raised. Unfortunately, it was not possible to sequence the genome as fast as it was expected ten years ago. Genome analysis has to be complemented with examinations of the tissue and the plasma proteins, in order to receive clear indications for a disease. It is the objective to provide every person with his or her own genome sequencing and with a map of plasma proteins in order to determine possible health-related risks.
Ruedi Aebersold
Rudolf Aebersold has been Full Professor of Systems Biology at the Institute of Molecular Biology & Biophysics at ETH Zurich since 1 November 2004.
He concluded his studies in 1979 at the University of Basle with a diploma in Cell Biology. In 1983 he obtained his PhD at the Biozentrum Basel. From 1984-88 Aebersold spent four years as a Postdoc and Senior Research Fellow at the California Institute of Technology in Pasadena.
From 1989-93 he held an Assistant Professorship in the Department of Biochemistry at the University of Washington in Seattle, where he consequently became Associate Professor from 1993-98 and Professor in the Department of Molecular Biotechnology from 1998-2000.
Since 2000 he has been Affiliate Professor at this university and co-founder of the Institute for Systems Biology in Seattle. Since 2001 Aebersold has also had a subsidiary teaching position at the University of Zurich. He has received many prizes along the way, amongst others, the MRC Candad Scholarship, the Killam Research Prize, the Pehr Edman Award, the American Society of Mass Spectrometry Biemann Medal and the Michael Widmer Award.
